A drug development perspective on targeting tumor-associated myeloid cells

Cancer immunotherapy targeting the CD47/SIRPα axis

(2017) Kipp Weiskopf   EUROPEAN JOURNAL OF CANCER

The efficacy of trabectedin in treating ovarian cancer

(2017) Eleonora Teplinsky et al.   EXPERT OPINION ON PHARMACOTHERAPY

Nanomedicine Strategies to Target Tumor-Associated Macrophages

(2017) Karin Binnemars-Postma et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies

(2017) Elie Dheilly et al.   MOLECULAR THERAPY

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin

(2017) Jun Chen et al.   NATURE

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

(2017) Jianjun Gao et al.   NATURE MEDICINE

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

(2017) Federica Recine et al.   OncoTargets and Therapy

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis

(2017) Takahiro Tsujikawa et al.   Cell Reports

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy

(2017) Yuting Huang et al.   Journal of Thoracic Disease

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

(2017) Michael A. Cannarile et al.   Journal for ImmunoTherapy of Cancer

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

SIRP -Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells

(2016) E. C. Piccione et al.   CLINICAL CANCER RESEARCH

Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis

(2016) Mehdi Brahmi et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists

(2016) Gregory L. Beatty et al.   Expert Review of Anticancer Therapy

Defects in CD4 + T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47 −/− mice from EAE

(2016) Veronica Azcutia et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers

(2016) Min Yao et al.   MODERN PATHOLOGY

Blocking the CCL2–CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model

(2016) Kun-Yu Teng et al.   MOLECULAR CANCER THERAPEUTICS

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

(2016) D. F. Quail et al.   SCIENCE

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

IFN  and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma

(2016) K. B. Long et al.   Cancer Discovery

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Unique features of trabectedin mechanism of action

(2015) Annette K. Larsen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy

(2015) Carola H Ries et al.   CURRENT OPINION IN PHARMACOLOGY

Targeting chemokines: Pathogens can, why can’t we?

(2015) Amanda E.I. Proudfoot et al.   CYTOKINE

Trabectedin for the treatment of breast cancer

(2015) Maurizio D’Incalci et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages

(2015) Zhiyuan Lv et al.   JOURNAL OF IMMUNOLOGY

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy

(2015) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

(2015) Philippe A Cassier et al.   LANCET ONCOLOGY

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys

(2015) S Dudal et al.   mAbs

Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer

(2015) Vincenzo Bronte et al.   NATURE MEDICINE

CD47 blockade as another immune checkpoint therapy for cancer

(2015) Robert H Vonderheide   NATURE MEDICINE

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

(2015) William D. Tap et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy

(2015) Lee B. Rivera et al.   Cell Reports

Original insights on thrombospondin-1-related antireceptor strategies in cancer

(2015) Albin Jeanne et al.   Frontiers in Pharmacology

Plasticity in Tumor-Promoting Inflammation: Impairment of Macrophage Recruitment Evokes a Compensatory Neutrophil Response

(2015) Jessica C. Pahler et al.   NEOPLASIA

Prognostic Value of Diametrically Polarized Tumor-Associated Macrophages in Renal Cell Carcinoma

(2014) Le Xu et al.   ANNALS OF SURGICAL ONCOLOGY

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment

(2014) M D’Incalci et al.   BRITISH JOURNAL OF CANCER

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

(2014) Carola H. Ries et al.   CANCER CELL

Monocyte subsets in man and other species

(2014) Loems Ziegler-Heitbrock   CELLULAR IMMUNOLOGY

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

(2014) Peter J. Murray et al.   IMMUNITY

Signal-regulatory proteinαfrom the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells

(2014) Lai Shan Kwong et al.   IMMUNOLOGY

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

(2014) Francois Moisan et al.   Molecular Oncology

Metastasis risk after anti-macrophage therapy

(2014) Ioanna Keklikoglou et al.   NATURE

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

(2014) Laura Bonapace et al.   NATURE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts

(2014) Marco Falasca et al.   Frontiers in Physiology

Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer

(2014) Emily K. Colvin   Frontiers in Oncology

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

(2013) Giovanni Germano et al.   CANCER CELL

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data

(2013) Gerald J. Fetterly et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clearing the Dead: Apoptotic Cell Sensing, Recognition, Engulfment, and Digestion

(2013) A. Hochreiter-Hufford et al.   Cold Spring Harbor Perspectives in Biology

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

(2012) Kenneth J. Pienta et al.   INVESTIGATIONAL NEW DRUGS

Macrophage plasticity and polarization: in vivo veritas

(2012) Antonio Sica et al.   JOURNAL OF CLINICAL INVESTIGATION

CD47Low Status on CD4 Effectors Is Necessary for the Contraction/Resolution of the Immune Response in Humans and Mice

(2012) Vu Quang Van et al.   PLoS One

Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature

(2012) Qiong-wen Zhang et al.   PLoS One

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

(2011) M. D. Michaelson et al.   ANNALS OF ONCOLOGY

COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells

(2011) M. Fujita et al.   CANCER RESEARCH

CD47: a new player in phagocytosis and xenograft rejection

(2011) Nalu Navarro-Alvarez et al.   Cellular & Molecular Immunology

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Monocyte Chemoattractant Protein–1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8+Cells

(2010) Zvi G. Fridlender et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation

(2010) K. P. A. MacDonald et al.   BLOOD

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

(2010) G. Germano et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth

(2010) J. Zhang et al.   JNCI-Journal of the National Cancer Institute

Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

(2010) Jasmine P. Davda et al.   mAbs

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

CD47 in the Immune Response: Role of Thrombospondin and SIRP-α Reverse Signaling

(2008) Marika Sarfati et al.   CURRENT DRUG TARGETS